Unite^® Biomatrix

Unite^® Biomatrix was launched in 2006 to provide an advanced biologic solution for chronic wound healing. Elevated levels of proteases in chronic wounds have made traditional collagen extracellular matrices (ECM) susceptible to rapid enzymatic breakdown, often requiring multiple reapplications. Flexibly crosslinked with proprietary technologies, Unite^® Biomatrix can be easily applied to the wound bed and is able to resist premature degradation caused by these elevated levels of enzymes. Clinical use suggests that this xenograft helps maintain the wound bed in the healing phase to support the growth of healthy granulation tissue and wound closure.

Chronic Wounds

The durable and sterile native collagen structure allows  Unite^® Biomatrix to be safely and easily applied to the debrided wound bed and maintain integrity as the wound heals, requiring only one application for most patients. Chronic wounds such as diabetic foot ulcers, venous ulcers, pressure ulcers, and vasculitic ulcers are growing clinical problems and Unite^® Biomatrix provides a new treatment solution.

Non-Reconstituted Type I Collagen
Unlike reconstituted collagen products, Unite^® Biomatrix is derived from native equine pericardium. This is a highly organized, Type I collagen matrix with a long history of use in implantable devices. The inherently superior physical properties enable this pliable <1mm thick xenograft to be securely and reliably affixed to the wound bed. Unite^® Biomatrix is available fenestrated or non-fenestrated. The fenestrated option assists in the management of wound exudate. Non-fenestrated Unite^® may be placed in a surgical mesher to expand coverage area.